Feb 3, 2026 08:01AM
Feb 3, 2026 08:00AM
Dec 29, 2025 08:00AM
Dec 29, 2025 08:00AM
Nov 12, 2025 08:00AM
May 27, 2025 08:01AM
May 27, 2025 08:00AM Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN
May 7, 2025 07:00AM
May 7, 2025 07:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM
Mar 6, 2025 04:10PM
Dec 5, 2024 08:00AM
Dec 5, 2024 08:00AM Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer
Nov 12, 2024 08:00AM
Oct 16, 2024 08:02AM
Oct 16, 2024 08:00AM
Sep 23, 2024 08:00AM
Aug 13, 2024 08:00AM
Jul 31, 2024 08:16AM
Jul 31, 2024 08:15AM Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
May 23, 2024 08:15AM
May 23, 2024 08:15AM
Nov 13, 2023 08:00AM
Aug 8, 2023 08:00AM
Jun 27, 2023 04:14PM
Jun 27, 2023 04:10PM
May 11, 2023 08:00AM Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results
Mar 30, 2023 08:00AM
Jan 17, 2023 08:00AM
Nov 10, 2022 04:45PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All